Cargando…

Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate

Among the agonists against three peroxisome proliferator-activated receptor (PPAR) subtypes, those against PPARα (fibrates) and PPARγ (glitazones) are currently used to treat dyslipidemia and type 2 diabetes, respectively, whereas PPARδ agonists are expected to be the next-generation metabolic disea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Honda, Akihiro, Kamata, Shotaro, Akahane, Makoto, Machida, Yui, Uchii, Kie, Shiiyama, Yui, Habu, Yuki, Miyawaki, Saeka, Kaneko, Chihiro, Oyama, Takuji, Ishii, Isao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102038/ https://www.ncbi.nlm.nih.gov/pubmed/35563117 http://dx.doi.org/10.3390/ijms23094726

Ejemplares similares

Functional and Structural Insights into the Human PPARα/δ/γ Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor
por: Kamata, Shotaro, et al.
Publicado: (2023)

Preparation of co-crystals of human PPARα-LBD and ligand for high-resolution X-ray crystallography
por: Kamata, Shotaro, et al.
Publicado: (2021)

Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
por: Kitamura, Shigeki, et al.
Publicado: (2023)

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study
por: Nakamura, Akihiro, et al.
Publicado: (2023)

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study
por: Nakamura, Akihiro, et al.
Publicado: (2023)

Event Monitoring and Evaluation by Community Pharmacists in Japan: A Pilot Study on Fenofibrate and Pemafibrate
por: Takahashi, Masao, et al.
Publicado: (2022)

A Mendelian randomization study for drug repurposing reveals bezafibrate and fenofibric acid as potential osteoporosis treatments
por: Li, Xiao-Hua, et al.
Publicado: (2023)

PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates
por: Kamata, Shotaro, et al.
Publicado: (2020)

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
por: Tenenbaum, Alexander, et al.
Publicado: (2005)

Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats
por: Khazaei, M., et al.
Publicado: (2012)

The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome
por: Huang, Yan, et al.
Publicado: (2017)

A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients
por: Yanai, Hidekatsu, et al.
Publicado: (2021)

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
por: Kamata, Shotaro, et al.
Publicado: (2023)

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Bezafibrate for X-Linked Adrenoleukodystrophy
por: Engelen, Marc, et al.
Publicado: (2012)

Therapy of Canine Hyperlipidemia with Bezafibrate
por: De Marco, V., et al.
Publicado: (2017)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Myelin Disruption, Neuroinflammation, and Oxidative Stress Induced by Sulfite in the Striatum of Rats Are Mitigated by the pan-PPAR agonist Bezafibrate
por: Glänzel, Nícolas Manzke, et al.
Publicado: (2023)

Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet
por: Horikawa, Tsuyoshi, et al.
Publicado: (2020)

Maternally inherited diabetes and deafness coexists with lipoprotein lipase gene mutation‐associated severe hyperlipidemia that was resistant to fenofibrate and atorvastatin, but sensitive to bezafibrate: A case report
por: Zhang, Xiaojuan, et al.
Publicado: (2021)

Effects and mechanisms of PPARα activator fenofibrate on myocardial remodelling in hypertension
por: Li, Chuan-Bao, et al.
Publicado: (2009)

Update on the use of fibrates: focus on bezafibrate
por: Goldenberg, Ilan, et al.
Publicado: (2008)

Metabolic effects of bezafibrate in mitochondrial disease
por: Steele, Hannah, et al.
Publicado: (2020)

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
por: Arai, Hidenori, et al.
Publicado: (2018)

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice
por: Araki, Masaya, et al.
Publicado: (2018)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

NO-Donating NSAIDs, PPARδ, and Cancer: Does PPARδ Contribute to Colon Carcinogenesis?
por: Mackenzie, Gerardo G., et al.
Publicado: (2008)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

PPAR-δ in Vascular Pathophysiology
por: Wang, Nanping
Publicado: (2008)

In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer
por: Saidi, Samir A, et al.
Publicado: (2006)

The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice
por: de la Rosa Rodriguez, Montserrat A., et al.
Publicado: (2018)

PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis
por: Bao, Wen, et al.
Publicado: (2021)

Erratum:A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

A novel selective PPARα modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms
por: Kawanishi, Hiroshi, et al.
Publicado: (2020)

Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content
por: Sasaki, Yusuke, et al.
Publicado: (2020)

Antidiabetic Action of Bezafibrate in a Large Observational Database
por: Flory, James H., et al.
Publicado: (2009)

I-3 Treatment of CPT2 deficiency with bezafibrate
por: Laforet, P.
Publicado: (2011)

Bezafibrate prevents aging in in vitro-matured porcine oocytes
por: Kim, Ju-Yeon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fs7eqoklhgcqggd29h4ljh6hma